| Kümmel, Sherko |
| Recruiting | 3 | 1260 | Europe | Abemaciclib 50 MG; 150mg 1-0-1 per os, Verzenios | West German Study Group, Eli Lilly and Company, Genomic Health®, Inc. | Breast Cancer Female | 08/26 | 03/28 | | |
ADAPTcycle, NCT04055493: Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC |
|
|
| Active, not recruiting | 3 | 1684 | Europe | Ribociclib 200Mg Oral Tablet, Kisqali | West German Study Group, Novartis, Genomic Health®, Inc. | Breast Cancer Female | 07/27 | 07/27 | | |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
| Active, not recruiting | 2 | 393 | Europe | Trastuzumab and Pertuzumab (FDC SC) and T-DM1, Trastuzumab emtansine, Phesgo, Kadcyla | MedSIR, Hoffmann-La Roche | Early Breast Cancer | 09/25 | 03/28 | | |
GeparPiPPa, NCT05306041: Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer |
|
|
| Recruiting | 2 | 170 | Europe | Inavolisib, PHESGO, Endocrine therapy | German Breast Group, Roche Pharma AG | HER2-positive Breast Cancer | 10/26 | 01/27 | | |
| Recruiting | 2 | 348 | Europe | Sacituzumab govitecan, Trodelvy, Pembrolizumab, Keytruda | West German Study Group, Gilead Sciences, Merck Sharp & Dohme LLC | Triple Negative Breast Cancer | 09/29 | 09/29 | | |
NCT06638307: A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer |
|
|
| Recruiting | 1 | 124 | Europe, US, RoW | MEN2312, Elacestrant | Stemline Therapeutics, Inc. | Advanced Breast Cancer | 10/25 | 10/26 | | |
CRANIO4US, NCT04319510: Supportive Effects of Craniosacral Therapy for Female Patients With Breast Cancer and Their Partners |
|
|
| Active, not recruiting | N/A | 102 | Europe | Craniosacral therapy, Craniosacral self-help group training, Treatment as usal / wait list | Universität Duisburg-Essen | Breast Cancer, Complementary Therapies | 07/25 | 12/25 | | |
NCT03463954: Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors |
|
|
| Recruiting | N/A | 122 | Europe, US | Novilase Laser ablation | Novian Health Inc. | Malignant Neoplasm of Breast | 09/25 | 09/25 | | |
TAXIS, NCT03513614: Tailored Axillary Surgery With or Without Axillary Lymph Node Dissection Followed by Radiotherapy in Patients With Clinically Node-positive Breast Cancer |
|
|
| Recruiting | N/A | 1500 | Europe, Canada, US, RoW | Tailored axillary surgery - both Arms, Radiotherapy - Arm A, Radiotherapy - Arm B | University Hospital, Basel, Switzerland, ETOP IBCSG Partners Foundation, Austrian Breast Cancer Study Group | Node-positive Breast Cancer | 12/29 | 12/36 | | |
OPBC-02PREPEC, NCT04293146: Pre- Versus Sub-pectoral Implant-based Breast Reconstruction After Skin-sparing Mastectomy or Nipple-sparing Mastectomy |
|
|
| Active, not recruiting | N/A | 382 | Europe, US | pre-pectoral IBBR, sub-pectoral IBBR | University Hospital, Basel, Switzerland, Swiss National Science Foundation | Breast Reconstruction, Implant-Based Breast Reconstruction (IBBR) | 05/25 | 02/33 | | |
| Hoffmann, Oliver |
CAPTOR-BC, NCT05452213: Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients |
|
|
| Recruiting | 4 | 1000 | Europe | Ribociclib | Institut fuer Frauengesundheit, AGO Breast Study Group e.V., Novartis Pharmaceuticals | Breast Cancer, Breast Neoplasms, Breast Neoplasm Female, Breast Cancer Female, HER2-negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Advanced Breast Cancer | 10/24 | 10/26 | | |
| Active, not recruiting | 3 | 654 | Europe, Canada, Japan, US, RoW | Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo | Seagen Inc., Merck Sharp & Dohme LLC | HER2 Positive Breast Cancer | 05/25 | 10/27 | | |
|
| Recruiting | 3 | 1260 | Europe | Abemaciclib 50 MG; 150mg 1-0-1 per os, Verzenios | West German Study Group, Eli Lilly and Company, Genomic Health®, Inc. | Breast Cancer Female | 08/26 | 03/28 | | |
| Active, not recruiting | 3 | 1332 | Europe | Capecitabine, Xeloda, Carboplatin, Paraplatin, Cisplatin, Platinol, Sacituzumab govitecan, Trodelvy | German Breast Group, Gilead Sciences, Austrian Breast & Colorectal Cancer Study Group, Spanish Breast Cancer Research Group (GEICAM), ETOP IBCSG Partners Foundation, Cancer Trials Ireland, UNICANCER | HER2-negative Breast Cancer, Triple Negative Breast Cancer | 03/27 | 03/29 | | |
ADAPTcycle, NCT04055493: Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC |
|
|
| Active, not recruiting | 3 | 1684 | Europe | Ribociclib 200Mg Oral Tablet, Kisqali | West German Study Group, Novartis, Genomic Health®, Inc. | Breast Cancer Female | 07/27 | 07/27 | | |
| Active, not recruiting | 2 | 393 | Europe | Trastuzumab and Pertuzumab (FDC SC) and T-DM1, Trastuzumab emtansine, Phesgo, Kadcyla | MedSIR, Hoffmann-La Roche | Early Breast Cancer | 09/25 | 03/28 | | |
ADAPTHER2-IV, NCT05704829: NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer |
|
|
| Recruiting | 2 | 402 | Europe | Trastuzumab deruxtecan, ENHERTU, Standard-of-Care, Chemotherapy+T+P | West German Study Group, AstraZeneca | HER2-positive Early Breast Cancer | 06/26 | 06/28 | | |
CRANIO4US, NCT04319510: Supportive Effects of Craniosacral Therapy for Female Patients With Breast Cancer and Their Partners |
|
|
| Active, not recruiting | N/A | 102 | Europe | Craniosacral therapy, Craniosacral self-help group training, Treatment as usal / wait list | Universität Duisburg-Essen | Breast Cancer, Complementary Therapies | 07/25 | 12/25 | | |
NCT04101851: Omission of SLNB in Triple-negative and HER2-positive Breast Cancer Patients with RCR and PCR in the Breast After NAST |
|
|
| Active, not recruiting | N/A | 350 | Europe | omission of SLNB | Toralf Reimer, MD PhD, European Breast Cancer Reseach Association of Surgical Trialists, University Medicine Rostock, Rostock, Germany (sponsor), Else Kröner-Fresenius-Stiftung (funding), German Society of Senology (funding) | Breast Cancer Female, Breast Cancer | 01/28 | 01/28 | | |
| Kimming, Klaus Rainer |
| No trials found |
